Drug
Shr 1210
Shr 1210: highest development phase Phase 3, developed by Jiangsu Hengrui Medicine. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| SHR-1210 NCT03813784 | Phase 3 | Gastric Cancer |
| SHR-1210 NCT03645876 | Phase 2 | Metastatic Colorectal Cancer |
| SHR-1210 NCT03558191 | Phase 2 | Nasopharyngeal Carcinoma |
Latest
No recent events.
Follow Shr 1210 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.